中国医学工程2026，Vol.34Issue(3)：34-39,6.DOI:10.19338/j.issn.1672-2019.2026.03.005
仑伐替尼、替雷利珠单抗及其联合治疗BCLC B/C期肝癌患者的疗效及安全性观察
Efficacy and safety of lenvatinib,tislelizumab and their combination in treatment of patients with BCLC stage B/C liver cancer
摘要
Abstract
[Objective]To investigate the efficacy and safety of lenvatinib,tislelizumab and their combination in the treatment of patients with Barcelona Clinic Liver Cancer(BCLC)stage B/C liver cancer.[Methods]A total of 120 patients with stage B/C liver cancer in the Sixth People's Hospital of Zhengzhou from April 2020 to April 2022 were selected and divided into three groups according to the random number remainder method,with 40 cases in each group.The patients were assigned to lenvatinib group with a remainder of 1 point,tislelizumab group with a remainder of 2 points,and combined group with a remainder of 0 points.The tumor remission status,adverse events and 2-year survival prognosis[progression-free survival(PFS),overall survival(OS)]were compared among the three groups of patients.[Results]During follow-up of this study,there were cases of shedding.Finally,37 cases in lenvatinib group,38 cases in tirelizumab group and 37 cases in combined group were included for statistical analysis.Compared with the tislelizumab group,the combined group had significantly higher partial remission rate,objective remission rate(ORR),and disease control rate(DCR),and a lower progressive disease(PD)rate(P<0.05).Compared with the lenvatinib group,the combined group also showed a lower PD rate and a higher DCR(P<0.05).There were no statistical differences in the incidence rates of adverse events among the three groups(P>0.05).After 24 months of follow-up,the median PFS in lenvatinib group was 13.4 months(95%CI:5.8-21.0),and that in tislelizumab group was 9.3 months(95%CI:6.2-12.4),and that in combined group was 21.3 months(95%CI:18.7-23.8),which was higher than the other two groups(log-rank χ2=8.646,P=0.013).There was no statistical significance in the median PFS between lenvatinib group and tislelizumab group(P>0.05).The median OS was 19.4 months(95%CI:15.2-23.6)in lenvatinib group and 17.5 months(95%CI:12.4-22.6)in tislelizumab group.The combined group did not reach the median OS at the end of follow-up.The survival prognosis in combined group was better than that in the other two groups(log-rank χ2=9.887,P=0.007),and no statistical difference was observed in the median OS between lenvatinib group and tislelizumab group(P>0.05).[Conclusion]The efficacy of lenvatinib combined with tislelizumab in the treatment of BCLC stage B/C liver cancer is better than that of monotherapy,which can improve ORR and DCR,and prolong PFS and OS.关键词
肝细胞癌/仑伐替尼/替雷利珠单抗/疗效/安全性Key words
hepatocellular carcinoma/lenvatinib/tislelizumab/efficacy/safety分类
医药卫生引用本文复制引用
孟雪,李广明,胡善雷,张敏敏..仑伐替尼、替雷利珠单抗及其联合治疗BCLC B/C期肝癌患者的疗效及安全性观察[J].中国医学工程,2026,34(3):34-39,6.基金项目
河南省2024年科技发展计划(242102310388) （242102310388）
